Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

1.0K
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
1.0K
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

3.0K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
3.0K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.8K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

2.2K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Systematic Review and Meta-Analysis on the Effectiveness of Interventions in Reducing Missed Opportunities for Vaccination Among Children Under Age Five.

Vaccines·2026
Same author

Understanding the roots of hesitancy to unlock the game-changing impact of HPV vaccination: Insights from a global qualitative evidence synthesis.

Human vaccines & immunotherapeutics·2026
Same author

Exploring the availability and content of vaccinology courses across the globe: A scoping review.

Human vaccines & immunotherapeutics·2026
Same author

Vaccine-Preventable Disease Control in the WHO African Region After the COVID-19 Public Health Emergency of International Concern: Implications for Recovery, Resilience, and System Transformation.

Vaccines·2026
Same author

Determinants of Missed Opportunities for Vaccination (MOVs) Indicators Among Children Aged 12-23 Months in Sub-Saharan African Countries: A Multilevel Analysis of Survey Data.

Vaccines·2026
Same author

Exploring perspectives of knowledge users about reporting on health equity in observational studies: a qualitative study informing the development of the STROBE-Equity reporting guideline.

International journal for equity in health·2026

Related Experiment Video

Updated: May 6, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K

β-Blockers as initial therapy for hypertension.

Charles S Wiysonge1, Lionel H Opie

  • 1Centre for Evidence-Based Health Care, Stellenbosch University, Cape Town, South Africa.

JAMA
|November 7, 2013
PubMed
Summary
This summary is machine-generated.

Beta-blockers do not lower mortality in hypertension but offer modest cardiovascular event reduction versus placebo. Other drug classes like calcium channel blockers provide greater benefits.

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

856
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.9K

Related Experiment Videos

Last Updated: May 6, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.6K
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

856
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.9K

Area of Science:

  • Cardiology
  • Pharmacology
  • Hypertension Management

Background:

  • Hypertension is a major risk factor for cardiovascular disease.
  • Initial pharmacologic treatment strategies significantly impact patient outcomes.
  • Beta-blockers have been a traditional choice for hypertension management.

Purpose of the Study:

  • To evaluate the efficacy of beta-blockers as initial hypertension therapy.
  • To compare beta-blockers against placebo, no treatment, and other antihypertensive drug classes.
  • To assess impact on all-cause mortality and cardiovascular events.

Main Methods:

  • Systematic review and meta-analysis of randomized controlled trials.
  • Inclusion of trials comparing beta-blockers with placebo, no treatment, or other antihypertensive agents.
  • Focus on studies reporting all-cause mortality and major cardiovascular events.

Main Results:

  • Initial beta-blocker therapy showed no reduction in all-cause mortality.
  • A modest reduction in cardiovascular events was observed compared to placebo or no treatment.
  • Calcium channel blockers and RAS inhibitors demonstrated superior cardiovascular event reduction versus beta-blockers.

Conclusions:

  • Beta-blockers are not associated with reduced all-cause mortality in initial hypertension treatment.
  • While offering some cardiovascular benefit, other drug classes are more effective.
  • Current evidence is limited to traditional beta-blockers, lacking data on newer agents.